K

KBI Biopharma

CDMO delivering cell line development

IBPE Senior Manager - Scenario Planning & Automation

Full-TimePosted on 10/22/2026
No salary listed
Expert
Bachelor's, Master's
Durham, NC, USA
In Person
Operations & LogisticsInventory Management, Supply Chain Management

About the job

Requirements
  • A Bachelor's degree in Supply Chain Management, Engineering, Computer Science, Information Systems, Business Analytics, Operations Management, or a related discipline is required.
  • At least 10 years of progressive experience in Supply Chain Planning, Inventory Management, Manufacturing Operations, Supply Chain Analytics, Procurement, Production Planning, or related functions is required.
  • Demonstrated expertise in supply chain management principles, including inventory optimization, procurement, manufacturing operations, material requirements planning, and capacity planning is required.
  • Experience leading complex cross-functional initiatives and driving measurable business outcomes is required.
  • Strong business acumen to connect operational decisions to financial results is required.
  • Analytical, problem-solving, communication, and influencing skills are required.
  • Ability to lead through influence and drive accountability across organizations without direct reporting relationships is required.
  • Advanced expertise in SAP ERP, including Production Planning, Materials Management, Inventory Management, material requirements planning, production orders, procurement processes, and master data governance is required.
  • Deep understanding of bills of material, routings, work centers, production versions, material master data, capacity planning, manufacturing execution processes, and supply chain planning logic is required.
  • Ability to challenge planning assumptions and validate SAP outputs through operational and technical expertise is required.
  • Advanced Python proficiency for scripting, ETL automation, data pipelines, data transformation, process automation, predictive analytics, supply chain modeling, and exception monitoring is required.
  • Advanced SQL proficiency for complex query development, data extraction, data transformation, data validation, reporting optimization, and large-scale data analysis is required.
  • Experience building scalable, production-ready analytical solutions is required.
  • Advanced experience developing material requirements planning simulations, inventory optimization models, capacity-constrained simulations, supply-demand balancing models, material availability models, inventory shelf-life forecasting models, supply chain risk models, and what-if scenario analysis tools is required.
  • Experience applying quantitative methods to support executive and operational decision-making is required.
  • Understanding of simulation techniques, sensitivity analysis, and supply chain optimization methodologies is required.
  • Experience with or working knowledge of AWS S3, AWS EC2, AWS Lambda, and AWS CloudWatch is required.
  • Understanding of data warehousing concepts, dimensional modeling, star schema design, data governance, and data quality management is required.
  • Practical experience applying software engineering best practices, including modular code development, Git/GitHub version control, CI/CD fundamentals, code testing and documentation, and production-ready solution development is required.
  • Advanced Power BI experience is required.
  • Experience developing executive dashboards and operational reporting solutions is required.
  • Ability to create KPI frameworks supporting proactive supply chain management and operational performance monitoring is required.
Responsibilities
  • Serve as the organization's central point of visibility for inventory, procurement, material availability, production readiness, and supply chain risk.
  • Establish proactive monitoring capabilities to identify operational risks, inventory exposures, system issues, and efficiency opportunities before they affect business performance.
  • Develop automated exception-management and risk-monitoring frameworks that provide real-time visibility into critical supply chain issues.
  • Translate complex supply chain data into actionable insights and lead corrective-action execution across the organization.
  • Own critical supply chain issues from identification through mitigation, resolution, validation, and closure.
  • Track operational and financial benefits realized through implemented improvements.
  • Drive initiatives to improve inventory efficiency, optimize working capital, and reduce excess, obsolete, and expiring inventory.
  • Develop visibility and control mechanisms for excess, obsolete, slow-moving, and expiring inventory; shelf-life extension opportunities; and material liability exposure.
  • Identify purchase orders requiring cancellation, rescheduling, delay, acceleration, or enhanced monitoring.
  • Lead implementation of inventory mitigation plans and procurement actions.
  • Partner with Procurement, Manufacturing, and Finance to optimize inventory investment while maintaining supply continuity.
  • Measure and report realized savings and inventory performance improvements resulting from implemented actions.
  • Serve as the business subject matter expert for SAP Production Planning, Materials Management, Inventory Management, and material requirements planning execution.
  • Evaluate planning inputs and outputs to ensure planning decisions are based on accurate and reliable data.
  • Analyze and resolve issues involving bills of material, routings, production versions, work centers, material master data, procurement master data, material requirements planning parameters, and lead-time assumptions.
  • Assess how SAP configurations and data structures affect inventory performance, procurement effectiveness, and manufacturing execution.
  • Drive system enhancements and process improvements that improve planning accuracy and operational efficiency.
  • Partner with IT and Digital teams to strengthen data integrity and planning system capabilities.
  • Lead development of advanced analytical and automation solutions for faster and more effective supply chain decision-making.
  • Design and implement automated data pipelines integrating ERP, planning, procurement, manufacturing, and operational data sources.
  • Eliminate manual reporting and repetitive analytical tasks through scalable automation solutions.
  • Use Python and SQL to develop automated reporting solutions, exception-monitoring systems, data-validation routines, inventory optimization models, supply chain performance dashboards, and predictive analytics tools.
  • Build and maintain executive dashboards supporting inventory management, procurement optimization, capacity planning, and supply chain risk management.
  • Collaborate with Digital, Data Engineering, and IT teams to establish sustainable analytical and reporting infrastructure.
  • Develop advanced simulation capabilities to support proactive supply chain decision-making.
  • Design and execute simulations evaluating demand variability, supplier delays, capacity constraints, material shortages, production bottlenecks, lead-time fluctuations, inventory policy changes, and shelf-life limitations.
  • Build material requirements planning simulation capabilities to improve planning accuracy and material availability assessments.
  • Develop capacity-constrained models to support manufacturing and production planning decisions.
  • Use scenario modeling, sensitivity analysis, and quantitative methods to evaluate operational and financial impacts.
  • Provide leadership with data-driven recommendations supported by advanced analytical and simulation models.
  • Develop methodologies that proactively identify supply chain risks and vulnerabilities.
  • Monitor material shortages, supplier performance issues, inventory liabilities, capacity limitations, and execution risks.
  • Lead cross-functional action plans to mitigate identified risks and drive timely resolution.
  • Establish accountability, milestones, and governance mechanisms for mitigation activities.
  • Track corrective-action effectiveness and validate expected outcomes.
  • Conduct post-resolution reviews to identify root causes and prevent recurrence.
  • Ensure high-priority supply chain risks are managed through closure and benefits are fully realized.
  • Partner with Supply Planning, Procurement, Manufacturing, Operations, Finance, Quality, Commercial Operations, and Digital organizations.
  • Influence organizational decisions through data-driven analysis and fact-based recommendations.
  • Lead cross-functional initiatives focused on operational efficiency, inventory optimization, and risk mitigation.
  • Present findings, business cases, risk assessments, and improvement opportunities to senior leadership.
  • Drive stakeholder alignment and execution of agreed-upon action plans.
  • Remove barriers to implementation of improvement initiatives and corrective actions.
Desired Qualifications
  • A Master's degree in Supply Chain Management, Engineering, Computer Science, Analytics, Operations Research, or Business Administration is preferred.
  • APICS/ASCM CPIM, CSCP, CLTD, or equivalent certification is preferred.
  • Lean Six Sigma Green Belt or Black Belt certification is preferred.
  • Experience in biotechnology, pharmaceuticals, cell and gene therapy, life sciences, diagnostics, or regulated manufacturing environments is preferred.
  • SAP S/4HANA experience is preferred.
  • Experience integrating ERP, manufacturing, planning, quality, and procurement data into enterprise analytical platforms is preferred.
  • Experience applying machine learning or artificial intelligence solutions within supply chain environments is preferred.

About the company

K

KBI Biopharma

View
Website

KBI Biopharma provides contract development and manufacturing services to help biotech and pharmaceutical companies turn scientific discoveries into biological medicines. The company uses mammalian and microbial expression systems to rapidly generate cell lines and develop the processes needed to produce recombinant proteins for preclinical programs. Unlike many competitors, KBI Biopharma offers a flexible range of both standalone and fully integrated development programs designed to meet strict budget and timeline requirements for diverse clients. Its goal is to reduce development risk and build value for partners while expanding global access to essential medicines.

Company Size

1,001-5,000

Company Stage

Late Stage VC

Total Funding

$109.5M

Headquarters

Durham, North Carolina

Founded

1996

Get referred to KBI Biopharma

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • JSR injected $99.87 million on October 1, 2025, funding growth and capacity.
  • KBI signed Kalaris in November 2025 and Infinimmune in September 2025.
  • Management expects double-digit 2026 growth from ADC expansion and APAC hiring.

What critics are saying

  • Tax Matrix sued KBI in 2024 for breach of contract, creating legal distraction.
  • KBI's workforce fell to 2,155 by March 2026, signaling operational pressure.
  • Biotech funding freezes can starve KBI's early-stage clients before clinical manufacturing begins.

What makes KBI Biopharma unique

  • KBI spans six global sites, serving 500+ partners across 170 drug candidates.
  • Its SUREmAb and integrated mammalian-microbial platforms accelerate cell line development and GMP manufacturing.
  • KBI won 2026 CDMO awards for fill-finish leadership and cultural fit.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Paid Vacation
  • Paid Holidays
  • Sabbatical Leave
  • Performance Bonus

Growth & Insights and Company News

6 month growth

0%

1 year growth

1%

2 year growth

0%
BioProcess International
Jun 25th, 2026
BPI theater insider interview, Sigma Mostafa, KBI Biopharma.

BPI theater insider interview, Sigma Mostafa, KBI Biopharma. KBI's chief scientific officer reflects on the company's 30 years of working with drug developers to translate key discoveries into viable medicines. June 25, 2026 11 Min View At the 2026 Biotechnology Innovation Organization (BIO) International Convention in San Diego, CA, KBI Biopharma chief scientific officer Sigma Mostafa sat down with BPI's Chris Spivey to reflect on how the company's mission and partnership philosophies have evolved over 30 years in the industry. KBI began as a company focused on centrifuge technology and, soon after, analytical services. When Mostafa joined in 2010, she helped to build the company into a contract development and manufacturing organization (CDMO) with comprehensive offerings. Today, the company operates six sites globally, with four commercial products and many development-stage projects in its pipeline. She noted that the company takes particular pride in the breadth and depth of its analytical capabilities, including centers of excellence in mass spectrometry, cell-based assays, and particle analysis for drug products. "Our unwavering focus on getting products from the cell-line stage all the way to the clinic has remained unchanged," Mostafa explained. However, the company's understanding of what that commitment means has deepened significantly. "It's not just a transactional relationship, but more of a strategic relationship with our partners." Learning through diverse experiences. Years of partnerships with a breadth of biotech companies have encouraged KBI to develop a consultative approach to process-development and manufacturing services. "We consider all customers to be our key customers essentially, small and big," Mostafa emphasized. Adopting that philosophy has required KBI "to meet the customer where their needs are," whether developers are driven by timelines, quality concerns, or fundraising challenges, as with early stage biotechs. That philosophy manifests in initiatives like the company's recently launched cell line development (CLD) rebate program, which offers a US$500,000 financial incentive for developers to partner with KBI from receipt of gene sequence for CLD through an initial good manufacturing practice (GMP) run for production of clinical-trial material. The program is designed to address current market realities, in which investors demand clinical data before funding additional activities. "We are committed to helping [clients] at a critical stage where a lot of them have to pause because of not having funding," Mostafa said. The rebate program essentially removes a significant financial barrier, enabling resource-constrained companies to bring candidates into the clinic. Measuring success differently. The CLD rebate program exemplifies how KBI defines success, Mostafa explained. KBI considers itself to be successful "if the molecule goes to clinic and moves all the way to market," which she opposed to a more standard mindset of asking, "'Did we we stay within scope, and did we do our little part of the work?" This perspective shift from task completion to patient impact, she noted, represents the culmination of three decades of working with customers with sometimes very different needs and goals.

Yahoo Finance
Mar 10th, 2026
HepaGam B market to surge on rising hepatitis B prevalence and global health initiatives

A market research report forecasts significant growth for HepaGam B, an immunoglobulin therapy for hepatitis B prevention, driven by rising disease prevalence and expanding healthcare initiatives. The World Health Organization reported 254 million people infected with hepatitis B in 2022, with 1.1 million deaths from related complications. Key growth drivers include increased healthcare worker safety measures, global health initiatives targeting hepatitis B elimination by 2030, and expanding plasma collection capacity. Kamada Limited recently opened a Houston facility to meet growing demand for plasma-derived products. North America held the largest market position in 2025, whilst Asia-Pacific is expected to experience the fastest growth. The market faces challenges including tariffs affecting plasma collection costs and production logistics, prompting increased domestic sourcing and manufacturing capacity expansion.

The Manila Times
Nov 12th, 2025
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Kalaris reports Third Quarter 2025 Financial Results and provides Business Updates. November 12, 2025 by year end 2025 Cash, cash equivalents and short-term investments of $77.0M as of September 30, 2025, expected to fund operations into 2027 Kalaris is currently evaluating TH103,adual-targeting biologic designed to achieve superior VEGF inhibition and extended intraocular durability through optimized binding to VEGF receptor 1 ligands and concurrent heparan sulfate proteoglycan (HSPG) anchoring BERKELEY HEIGHTS, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) - Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the third quarter ended September 30, 2025, and provided business updates. "The third quarter marked an important inflection point for Kalaris," said Andrew Oxtoby, Chief Executive Officer of Kalaris Therapeutics. "Most importantly, we began enrolling our Phase 1b/2 multiple ascending dose trial of TH103 in neovascular age-related Macular Degeneration (nAMD). This Phase 1b/2 trial is designed to build on our ongoing Phase 1a single ascending dose trial; we look forward to reporting initial clinical data from our Phase 1a trial by the end of this year, including safety, preliminary efficacy (e.g., visual acuity and lesion morphology), and pharmacokinetics." In addition to progressing TH103's clinical development program, Kalaris also entered a formal agreement with KBI Biopharma for clinical supply manufacturing. Mr. Oxtoby stated, "Working with KBI is an important step as we progress into a later stage biotech company. Our decision to work with KBI reflects their deep technical expertise to support continued development of TH103." Katie Edgar, Chief Business Officer of KBI Biopharma, said, "We look forward to applying our scientific and regulatory acumen to helping progress Kalaris' exciting product candidate. Our agreement with Kalaris reflects our shared commitment to patient impact." Business Updates * Initial clinical data from the Phase 1a clinical trial expected by year end 2025. The single ascending dose trial followed patients after a single injection of TH103 to assess the safety, pharmacokinetics, and preliminary treatment effect of TH103 in treatment naïve nAMD patients. * Newly initiated Phase 1b/2 dose-finding clinical trial is designed to evaluate multiple dose levels of TH103 in up to 80 nAMD patients. Patients are expected to receive 4 initial monthly intravitreal injections of TH103. Study assessments are expected to include safety and preliminary efficacy with a primary time point for analysis at one-month following the last injection with patients followed thereafter in an extension phase. * KBI Biopharma, based in North Carolina, selected as Kalaris' Contract Development and Manufacturing Organization (CDMO) for clinical supply manufacturing of TH103. * As previously announced, Kalaris expanded its leadership team with the hire of Matthew Gall, Chief Financial Officer. Mr. Gall has over 20 years of corporate finance experience, including business development transactions and financial operations and strategy for both small and large biopharmaceutical companies. * New corporate headquarters opened in Berkeley Heights, New Jersey. Financial Results for the Third Quarter Ended September 30, 2025 Cash, Cash Equivalents and Short-Term Investments: As of September 30, 2025, Kalaris had cash, cash equivalents and short-term investments of $77.0 million, compared with cash and cash equivalents of $1.6 million as of December 31, 2024. The increase in cash and cash equivalents was primarily a result of the completion of its merger with AlloVir in Q1 2025. Kalaris expects that its cash, cash equivalents and short-term investments as of September 30, 2025 will be sufficient to fund its operations into 2027. Research and Development Expenses: Research and development expenses were $9.1 million for the quarter ended September 30, 2025, compared with $36.0 million for the quarter ended September 30, 2024. The decrease quarter-over-quarter was primarily attributable to a $32.0 million royalty obligation expense for a Royalty agreement entered into with Samsara in July 2024, offset by an increase in costs related to the outsourcing of manufacturing and clinical-related costs to support the ongoing Phase 1a and the newly initiated Phase 1b/2 clinical trial. General and Administrative Expenses: General and administrative expenses were $3.6 million for the quarter ended September 30, 2025, compared with $1.8 million for the quarter ended September 30, 2024. The increase quarter-over-quarter was primarily attributable to an increase in insurance, legal, accounting, and professional fees and personnel related costs to support operating as a public company. Net Loss: For the quarter ended September 30, 2025, net loss was $11.9 million compared with a net loss of $38.1 million for the quarter ended September 30, 2024. The total number of shares of common stock outstanding as of September 30, 2025 was 18,702,418. About Kalaris Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risk and uncertainties. All statements, other than statements of historical fact, contained in this press release, including statements regarding the strategy, future operations, prospects, plans and objectives of management of Kalaris, including the therapeutic potential of TH103 for nAMD and other exudative and neovascular retinal diseases, the anticipated timelines for reporting clinical data from the Phase 1a and Phase 1b/2 clinical trials of TH103, plans to advance TH103 into Phase 3 clinical trials and to develop TH103 for additional indications and the sufficiency of Kalaris' cash resources for the period anticipated, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are based on current expectations and beliefs of the management of Kalaris as well as assumptions made by, and information currently available to, the management of Kalaris and are subject to risks and uncertainties. There can be no assurance that future developments affecting Kalaris will be those that it has anticipated. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: risks associated with the clinical development and regulatory approval of TH103, including potential delays in the completion of clinical trials; expectations regarding the therapeutic benefits, clinical potential and clinical development of TH103; risks related to the inability of Kalaris to obtain sufficient additional capital to continue to advance its product candidate; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from any product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; the ability to obtain, maintain, and protect intellectual property rights related to product candidates; changes in regulatory requirements and government incentives; Kalaris' competitive position and expectations regarding developments and projections relating to its competitors and any competing therapies that are or become available; potential adverse reactions or changes to business relationships resulting from the completion of the merger with AlloVir, Inc.; risks associated with the possible failure to realize, or that it may take longer to realize than expected, certain anticipated benefits of the merger, including with respect to future financial and operating results; the risk of involvement in current and future litigation, including securities class action litigation; and such other factors as are set forth in Kalaris' public filings with the SEC, including, but not limited to, those described under the heading "Risk Factors". Kalaris may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release, and Kalaris does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

MarketScreener
Oct 1st, 2025
KBI Biopharma secures $99.87M funding

KBI Biopharma, Inc. announced it received $100 million in funding from JSR Corporation on October 1, 2025. JSR Corporation, which holds 100% voting rights in KBI Biopharma, participated as a returning investor. The company issued convertible preferred stock, increasing its capital from $0.1 to $99.9 million.

BioProcess International
Dec 4th, 2024
ATI and KBI team up to manufacture antagonistic antibody candidate

Alanis Therapeutics (ATI) signed a manufacturing agreement with contract development and manufacturing organization (CDMO) KBI Biopharma, to develop and manufacture its lead candidate preclinical antibody.